Solvonis Therapeutics (SVNS) AI Stock Analysis

• Market Cap: £16.34M
• Dividend Yield: N/A
• Average Volume (3M): 34.43M
• Price to Earnings (P/E): ―
• Beta (1Y): -1.29
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: 3
• Sector: Industrials
• Sector Strength: 72
• Industry: Industrial - Machinery
• EPS (TTM): 0.00
• Shares Outstanding: 6,806,403,300
• 10 Day Avg. Volume: 23,401,787
• 30 Day Avg. Volume: 34,434,652
• PEG Ratio: 0.02
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 50 Neutral
• Price Target: 0.26 p ▼(-25.71% Downside)
• Action: N/A Date: 01/04/26
• Date: Action: N/A 01/04/26

The score is held down primarily by weak fundamentals (zero revenue in 2024, ongoing losses, and continued cash burn), despite the benefit of a low-debt balance sheet. Technical indicators are supportive (price above key moving averages with positive MACD), but missing P/E and dividend yield data limits valuation assessment.

Positive Factors

Low Leverage

Zero reported debt in 2024 and generally low leverage reduce solvency risk and lower fixed financing obligations. This durable balance-sheet strength gives management flexibility to pursue financing or strategic options without immediate refinancing pressure, a structural buffer versus leveraged peers.

Improving Cash Flow Trend

Free cash flow improvement year-over-year signals initial cost controls or operational efficiency gains. If sustained, this structural improvement can lengthen runway, reduce future external funding needs, and support a transition toward self-funded operations over the medium term.

Lean Cost Base

A three-person workforce implies an extremely lean operating model with low fixed personnel costs. Structurally low headcount can materially extend cash runway, allow rapid reallocation of resources, and provide flexibility while management seeks a viable revenue model or strategic partner.

Negative Factors

Zero Revenue

Revenue dropping to zero in 2024 removes the company's operating income base and eliminates margin generation. Without recurring sales, the business lacks customer validation and predictable cash inflows, making medium-term viability contingent on restoring sustainable revenue sources.

Persistent Losses and Cash Burn

Ongoing operating and net losses with materially negative operating cash flow demonstrate continued capital consumption. This pattern forces dependence on external financing, limits the company's ability to invest in growth or R&D, and raises execution risk if losses persist over multiple quarters.

Eroding Equity Base

Declining equity and asset bases alongside strongly negative ROE indicate the capital base is being consumed rather than compounded. This structural erosion reduces financial flexibility, increases the likelihood of dilution or distress financing, and constrains strategic choices over time.

Solvonis Therapeutics Business Overview & Revenue Model

Company Description

Solvonis Therapeutics plc, together with its subsidiaries, researches and develops polymer modification technologies and techniques in the United Kingdom, Slovenia, and Europe. The company offers GRAFTABOND, a line of graft/block copolymers for combining various polymers with fiberglass, carbon fiber, mineral, natural fillers, and mixed polymer waste; GRAFTALEN, a line of reactive solid super-concentrates for polyolefin rheology modification, e-modulus enhancers, PET/PBT chain extenders, and AOX masterbatch; and GRAFTAPOR, a line of porous polymer-carriers for use in liquid chemicals. It also provides GRAFTAMID, a line of high-temperature elastomers based on nanostructured polyolefin-polyamide alloys for high-tech hardening modifiers in polyamide compounds, as well as use as an independent compound in hot melt adhesives; and GRAFTAKIT, a reactive liquid or solid super-concentrates on polymeric porous media for carrying out reaction extrusion and modification of compounds. In addition, the company offers GRAFTALLOY, a line of polymer-polymer nano-alloys to increase abrasion and temperature resistance, and impact strength, as well as reduce friction coefficient; GRAFTASYNT, a line of synthetic products comprising halogen-free flame retardants; and GRAFTAMER, a thermo-reversible crosslinking, self-hardening, and self-healing smart polymer with shape memory, etc. The company was formerly known as Graft Polymer (UK) Plc and changed its name to Solvonis Therapeutics plc in January 2025. Solvonis Therapeutics plc was incorporated in 2017 and is headquartered in London, the United Kingdom.

Solvonis Therapeutics Financial Statement Overview

Summary

Financial performance is weak: persistent operating/net losses and 2024 revenue falling to zero. Cash flow remains meaningfully negative (operating and free cash flow ~-1.13M in 2024), indicating ongoing cash burn. The main offset is low leverage (2024 total debt is zero), but declining equity/assets and negative returns reflect continued capital erosion.

Income Statement

Profitability remains weak with persistent operating and net losses across all reported periods (e.g., 2024 net loss of ~1.6M). Revenue momentum deteriorated materially, with 2024 revenue falling to zero after modest revenue levels in 2022–2023. Margins are deeply negative in most years and effectively non-existent in 2024 due to no revenue, though the net loss did narrow versus 2023—showing some cost progress, but not a sustainable earnings base yet.

Balance Sheet

The balance sheet is a relative bright spot: leverage is low in recent years (2024 total debt is zero; 2023 debt-to-equity is near zero), which reduces solvency risk. However, equity and assets have trended down versus 2022, and returns on equity are strongly negative due to ongoing losses—highlighting that the capital base is being consumed rather than compounded.

Cash Flow

Cash generation is consistently negative, with operating cash flow and free cash flow remaining meaningfully below zero (2024 operating cash flow ~-1.13M; free cash flow ~-1.13M). Free cash flow improved versus 2023, but the business is still cash-burning and likely reliant on external funding. Cash flow is not yet demonstrating a durable inflection toward self-funding operations.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	May 2021
Income Statement
Total Revenue	0.00	587.00K	542.00K	219.00K	690.86K
Gross Profit	0.00	-134.00K	-51.00K	55.00K	517.72K
EBITDA	-1.38M	-2.94M	-2.59M	-900.00K	-322.29K
Net Income	-1.59M	-3.12M	-2.71M	-954.00K	-274.29K
Balance Sheet
Total Assets	3.20M	2.43M	4.94M	3.13M	2.77M
Cash, Cash Equivalents and Short-Term Investments	757.00K	155.00K	1.64M	598.00K	209.00K
Total Debt	0.00	34.00K	22.00K	950.00K	654.00K
Total Liabilities	119.00K	408.00K	385.00K	2.32M	1.22M
Stockholders Equity	3.08M	2.03M	4.55M	812.00K	1.54M
Cash Flow
Free Cash Flow	-1.13M	-1.47M	-3.08M	-255.00K	-15.00K
Operating Cash Flow	-1.13M	-1.24M	-2.36M	-254.00K	1.00K
Investing Cash Flow	-337.00K	-232.00K	-718.00K	-1.00K	-16.00K
Financing Cash Flow	2.08M	0.00	4.13M	800.00K	199.00K

Solvonis Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMI	74 Outperform	£6.56B	20.02	24.91%	1.29%	-0.32%	-3.96%
AVG	70 Outperform	£179.65M	10.69	6.13%	1.02%	14.49%	76.33%
SMIN	66 Neutral	£7.40B	29.17	13.46%	1.93%	-6.93%	18.57%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
MGAM	62 Neutral	£555.19M	28.89	8.04%	4.87%	-7.30%	-59.71%
MPAC	61 Neutral	£87.96M	-2.99	-17.46%	―	21.17%	-237.25%
SVNS	50 Neutral	£16.34M	―	-62.23%	―	―	―

Solvonis Therapeutics Corporate Events

Solvonis names patented PTSD drug candidate SVN‑114 as lead asset

Solvonis Therapeutics has selected SVN‑114 as the lead candidate in its Post‑Traumatic Stress Disorder discovery programme, following preclinical work showing balanced modulation of serotonin, dopamine and noradrenaline systems. The compound comes from the company’s proprietary SVN‑SDN‑14 series, designed to enhance pro‑social behaviour and improve engagement with therapy in patients with PTSD, a condition with limited effective pharmacological options.

SVN‑114 is supported by international composition‑of‑matter patent applications covering both the chemical class and its therapeutic uses, giving Solvonis a strong intellectual property position in trauma‑related psychiatric disorders. Management and scientific leadership say the decision marks a key milestone for the company’s CNS discovery platform and could help position Solvonis for first‑ or best‑in‑class treatments in a large, underserved and growing global mental‑health market.

The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.26 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.

Solvonis Extends Novel SDRI SVN‑015 Into Depression After Positive Preclinical Results

Solvonis Therapeutics has expanded development of its investigational compound SVN‑015 into depression after preclinical studies in validated rodent behavioural models showed antidepressant‑like activity comparable to the widely used SSRI fluoxetine following 14 days of once‑daily dosing. SVN‑015, a novel serotonin‑dopamine reuptake inhibitor designed for once‑daily oral use at home, is being positioned as a potential new class of antidepressant particularly for patients with inadequate response to SSRIs, targeting symptoms such as anhedonia and reduced motivation, and its progress adds to Solvonis’s broader CNS franchise, which also includes NIDA‑backed work in stimulant use disorders and could strengthen the company’s positioning and partnering prospects in the competitive market for mood and addiction therapies.

The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.27 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.

Solvonis Wins U.S. Patent Boost for Novel PTSD Drug Programme

Solvonis Therapeutics has received a Notice of Allowance from the U.S. Patent and Trademark Office covering a novel series of compounds within its SVN-SDN-14 PTSD discovery programme, bolstering the intellectual property position of this early-stage asset as the company moves toward selecting a lead candidate in the first quarter of 2026. The newly protected compounds are designed to modulate serotonin, dopamine and noradrenaline pathways while offering improved pharmacokinetic control through predictable metabolic deactivation, a feature the company says could translate into safer, more flexible dosing and greater real-world clinical utility, strengthening both the scientific validation and commercial prospects of Solvonis’s PTSD franchise in the competitive CNS therapeutics landscape.

The most recent analyst rating on (GB:SVNS) stock is a Hold with a £0.32 price target. To see the full list of analyst forecasts on Solvonis Therapeutics stock, see the GB:SVNS Stock Forecast page.

Solvonis Therapeutics Maps Out Catalyst-Rich 2026 as CNS Pipeline Gains Momentum

Solvonis Therapeutics reported broad progress across its CNS pipeline as it heads into what it describes as a catalyst-rich 2026, highlighting advancement of its lead alcohol use disorder (AUD) and PTSD programmes alongside AI-driven discovery efforts. Lead candidate SVN-001 is moving through a potentially pivotal Phase 3 trial for severe AUD in a large, underserved UK and EU population, while SVN-002, an esketamine oral thin film for moderate-to-severe AUD, is being prepared for a U.S. Phase 2b trial via an FDA 505(b)(2) pathway that could materially reduce development time and cost. The company also secured external validation for its AI-enabled platform with SVN-015’s acceptance into the U.S. National Institute on Drug Abuse’s Addiction Treatment Discovery Program, which brings NIDA-funded preclinical work and potential access to further non-dilutive NIH development funding for stimulant use disorder. Meanwhile, PTSD candidate SVN-SDN-14 is nearing lead selection ahead of IND-enabling studies, and Solvonis says the integration of Awakn Life Sciences earlier in 2025 has created a more diversified CNS platform, positioning the group with multiple regulatory, preclinical and partnering milestones that could enhance both its industry standing in addiction psychiatry and its long-term value proposition for shareholders.